Calcium Antagonists In The Treatment Of Hypertension In Pregnancy

This is a clinician's and researcher's reference text on using calcium antagonists - calcium channel blockers - in the treatment of gestational hypertension and pre-eclampsia. It contains twelve chapters covering experimental and clinical studies on the major calcium antagonists, their definition and classification and pharmacological profile, which drugs to use and when and which drugs to avoid. It also describes nifedipine pharmacodynamics and pharmacokinetics and covers nifedipine first-line treatment of gestational hypertension and pre-eclampsia along with chapters on second-line treatment and nifedipine blood cells and blood rheology. The book provides a comparison between two calcium antagonists in treating gestational hypertension and new categories to classify pre-eclampsia. Includes bibliographic references and index.

Hypertensive disorders of pregnancy are an important cause of severe morbidity, long-term disability and death among both pregnant women and their babies, and account for approximately 14% of all maternal deaths worldwide. Improving care for women around the time of childbirth is a necessary step towards achievement of the health targets of the Sustainable Development Goals (SDGs). Efforts to prevent and reduce morbidity and mortality during pregnancy and childbirth could also help address the profound inequities in maternal and perinatal health globally. To achieve these goals, healthcare providers, health managers, policy-makers and other stakeholders need up-to-date and evidence-based recommendations to inform clinical policies and practices. In 2019, the Executive Guideline Steering Group (GSG) on WHO maternal and perinatal health recommendations prioritized issuing new WHO recommendations on antihypertensive drugs for non-severe (mild to moderate) hypertension during pregnancy in response to new important evidence on this intervention. For this guideline, non-severe hypertension and mild to moderate hypertension is used interchangeably, defined as diastolic blood pressure of 90–109 mmHg.

This thoroughly revised and expanded new edition presents the current state of knowledge of the diverse applications of calcium antagonists and makes recommendations about their appropriate use. Chapters have been added to critically review the new applications of these agents and to address the concept of fixed-dose formulations--the combination of calcium antagonists with ACE inhibitors or beta blockers.

Chesley’s Hypertensive Disorders in Pregnancy continues its tradition as one of the beacons to guide the field of preeclampsia research, recognized for its uniqueness and utility. Hypertensive disorders remain one the major causes of maternal and fetal morbidity and death. It is also a leading cause of preterm birth now known to be a risk factor in remote cardiovascular disease. Despite this the hypertensive disorders remain marginally studied and management is often controversial. The fourth edition of Chesley’s Hypertensive Disorders in Pregnancy focuses on prediction, prevention, and management for clinicians, and is an essential reference text for clinical and basic investigators alike. Differing from other texts devoted to preeclampsia, it covers the whole gamut of high blood pressure, and not just preeclampsia. Features new chapters focusing on recent discoveries in areas such as fetal programming, genomics/proteomics, and angiogenesis Includes extensive updates to chapters on epidemiology, etiological considerations, pathophysiology, prediction, prevention, and management Discusses the emerging roles of metabolic syndrome and obesity and the increasing incidence of preeclampsia Each section overseen by one of the editors; each chapter co-authored by one of the editors, ensuring coherence throughout book

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series